Drug Profile
Research programme: IgA protease - BioMarin/IGAN
Alternative Names: BMN-185; BMN-185 - IgA ProteaseLatest Information Update: 01 Apr 2011
Price :
$50
*
At a glance
- Originator BioMarin Pharmaceutical; IGAN Biosciences
- Class Peptide hydrolases
- Mechanism of Action Peptide hydrolase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported IgA nephropathy
Most Recent Events
- 31 Dec 2010 No development reported - Preclinical for IgA nephropathy in USA (Parenteral)
- 03 Dec 2007 Preclinical trials in IgA nephropathy in USA (Parenteral)